- Home
- SLMBP vs TXMD Comparison
SLMBP vs TXMD Comparison
Compare SLMBP & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMBP | TXMD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 24.3M |
| IPO Year | 1997 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SLMBP | TXMD |
|---|---|---|
| Price | $74.30 | $2.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 30.3K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.10 | ★ 73.68 |
| EPS | ★ 1.85 | 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $40.15 | $109.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $70.58 | $0.99 |
| 52 Week High | $76.30 | $2.95 |
Technical Indicators
Market Signals| Indicator | SLMBP | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 54.98 |
| Support Level | $74.51 | $2.07 |
| Resistance Level | $75.19 | $2.30 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 72.05 | 45.83 |
Price Performance
Historical ComparisonAbout SLMBP SLM Corporation Floating Rate Non-Cumulative Preferred Stock Series B
SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.